Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
View: Text | PDF
Research Article Cell biology Oncology

Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence

  • Text
  • PDF
Abstract

Chordomas are rare malignant osseous neoplasms with a striking rate of recurrence. Primary chordomas typically originate from embryonic notochord remnants, whereas recurrent chordomas usually stem from tumor cells infiltrating bone or cartilage after surgery. Clinically, the recurrent chordomas exhibit a stiffer extracellular microenvironment (ECM) than primary tumors. Intriguingly, this study identified cytoskeleton rearrangement, stress fiber reorganization, enhanced stemness, and Notch signaling activation in recurrent chordoma tissues or cell lines surviving stiff substrates, indicating the critical roles of mechanical remodeling and tumor stemness in stiffness resistance. We propose a potentially novel recurrence model where tumor cells experience mechanoadaptive organization, which enables them to resist stiff microenvironment-induced cell death. O-GlcNAcylation of Notch1 intracellular domain (NICD1) is central to this process. Mechanistically, the stiff ECM-driven ligand-independent phosphorylation of EPHA2 sequentially activated LYN kinase and subsequently triggered O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) activity by phosphorylating Y989 and Y418, critical residues for OGT glycosyltransferase activity; this induced NICD1 O-GlcNAcylation at T2063, T2090, and S2162, specifically promoting transcription of mechanical and stemness-related genes. MIR31 deletion upregulated LYN, enhancing stiffness perception and promoting O-GlcNAc addition to NICD1, finally resulting in mechanoadaptation- and tumor stemness–driven recurrence. Consequently, MIR31 deletion is a potential biomarker for recurrence and patient stratification in Notch- or OGT-targeted therapies.

Authors

Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu

×

Figure 7

Deletion of MIR31 contributes to LYN upregulation in recurrent chordoma.

Options: View larger image (or click on image) Download as PowerPoint
Deletion of MIR31 contributes to LYN upregulation in recurrent chordoma....
(A) IHC was used to analyze LYN expression in primary and recurrent chordoma tissues in clinic (n = 20 pairs). The solid line represents the mean value. (B) Duolink PLA was used to determine the level of NICD1 O-GlcNAcylation in chordoma. LYN expression was assessed using IHC. The median values of LYN and NICD1 O-GlcNAcylation were used as the cut-off values. N = 87. Scale bar: 50 μm. (C) Kaplan-Meier analysis of recurrence-free survival and overall survival. Patients with chordoma were grouped according to the LYN level detected by IHC. Median survival time and horizon risk (HR) of recurrence and death are listed. (D) IP was used to determine the effects of LYN, OGT, and OSMI-1 on miR-31 mimic-regulated NICD1 O-GlcNAcylation. (E) Dual luciferase assay was used to assess the effects of LYN, OGT, WT NICD1, and T2063A/T2090A/S2162A (MT) NICD1 on Notch signaling activity. (F) TUNEL assay results from cells cultured on substrates with different stiffnesses and indicated treatments. (G) Fluorescence in situ hybridization was used to determine levels of genomic MIR31 in paired primary and recurrent chordoma tissues. Scale bar: 10 μm. (H) Patients with chordoma grouped by level of MIR31 determined by qRT-PCR (n = 87). LYN protein expression was determined by IHC. NICD1 O-GlcNAcylation level was determined by Duolink PLA. (I) Kaplan-Meier analysis of recurrence-free survival and overall survival. Patients with chordoma were grouped according to the MIR31 DNA level detected by qRT-PCR. Median survival time and HR of recurrence and death are listed. (J and K) 107 MUG-Chor1 cells were inoculated subcutaneously. Tumors were treated with PUGNAC (50 μM), GlcNAc (10 μM), or miR-31 agomir (1 mg/mL). After 6 weeks, cisplatin (cis-diamminedichloroplatinum, 4 mg/kg) was intraperitoneally injected every 3 days (n = 5/group). (J) Representative bioluminescent images of subcutaneous tumors with indicated treatment at 12 weeks are shown, and the tumor weight is presented. (K) Expression of Notch downstream genes and CSC- and mechanical-related genes was assessed using qRT-PCR. Data in A are presented as mean (minimum to maximum). Data in E, F, J, and K are presented as mean ± SD. Statistical analysis was performed using paired Student’s t test (A), χ2 test (B and H), and 1-way ANOVA (E, F, J, and K). *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts